Our in vivo and in vitro studies showed that Y-27632 or selective inhibition of ROCK1 and ROCK2 may exert potential therapeutic effects in BPH by regulating cell growth, fibrosis, and EMT. Here, ROCK1 is linked to benign prostatic hyperplasia.